Allergan
- AGN
- NYSE
- Consumer Products
- Latest 101.49
- Currency US$
- Change 0.01
- Percent Change 0.01 %
- Volume 1,874,063
- Tue Jun 18, 2013 4:03 PM EDT NYSE data delayed 15 minutes.
The Globe and Mail
- Open 101.80
- Previous Close 101.48
- High 102.17
- Low 100.66
- Bidx2 95.01
- Askx7 104.41
- 52-week High 04/11 116.45
- 52-week Low 07/31 81.28
- Beta 0.62
- Market Cap 30,212.56M
- EPS 3.96
- P/E 25.63
- Forward P/E 18.588
- PEG 1.57
- Annual Dividend 0.20
- Yield 0.197
News
- Gastric banding: Pros and cons of Christie's surprising choice
- UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea
- REFILE-UPDATE 2-Allergan delays drug that would rival Regeneron's Eylea
- UPDATE 2-Allergan delays drug that would rival Regeneron's Eylea
- UPDATE 1-Allergan delays eye drug, shares fall
- FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face
- Allergan Reports First Quarter 2013 Operating Results
- Allergan Announces Death of Stephen J. Ryan, M.D.
- Allergan Announces Quarterly Conference Call
- Allergan, Inc. Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. and Intent to Exercise Top-Up Option to Effect a Short-Form Merger
Financials & Calendars
- Sales $5,873,800,000
- Earnings $881,500,000
- Return on Equity 15.71%
- Cash Flow --
- Cash $2,198,800,000
- Current Ratio 3.83
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $9,250,500,000
- Liabilities $3,888,100,000
- Liabilities-to-Equity Ratio 0.73
Price Ratios
- Price to Sales 5.14
- Price to Book 5.63
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 1 | $0.96 | Aug 7 | $1.20 |
| Surprises | May 1 | 2.08% | n/a | n/a |
| Dividends | May 21 | $0.05 | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended Jun 19, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Allergan, Inc. is a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets. Its worldwide consolidated revenues are principally generated by prescription and non-prescription pharmaceutical products in the areas of ophthalmology and skin care, neurotoxins, intraocular lenses and other ophthalmic surgical products, and contact lens care products.
Officers
- David E.I. Pyott Chmn; C.E.O. & Presi
- Herbert W. Boyer, Ph.D., Vice Chairman of the Board
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
2525 DUPONT DRIVEIRVINE, CA
92713-9
Phone: 7142464500
Fax: (714)-2466987
Ideas & Discussion
Live Discussion of AGN on StockTwits